Table 1. Characteristics of patients used for validation of the database-guided analysis.
Parameter | Validation cohort | Databasea | Total | |
---|---|---|---|---|
WHO diagnosis (n) | T-ALL | 46 | 145 | 191 |
BCP-ALL | 158 | 377 | 535 | |
AML | 523b | 134 | 657 | |
MPAL | 55 | 0 | 55 | |
AUL | 1 | 0 | 1 | |
Gender (n) | F | 326 | 265 | 591 |
M | 455 | 389 | 844 | |
Unknown | 2 | 2 | 4 | |
Age (years) | Median | 39 | 6 | 10 |
Range | 0-95 | 0-84 | 0-95 | |
WBC (109/l) | Median | 19.8 | 14 | 16 |
Range | 0.5-754 | 1–1000 | 0.5–1000 | |
Disease phase (n) | Diagnosis | 767 | 634 | 1401 |
Relapse | 12 | 21 | 33 | |
Unknown | 4 | 1 | 5 | |
Sample type (n) | Bone marrow | 695 | 586 | 1280 |
Peripheral blood | 87 | 68 | 155 | |
Otherc | 1 | 2 | 3 |
Abbreviations: AML, acute myeloid leukemia; AUL, acute undifferentiated leukemia; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; MPAL, mixed phenotype acute leukemia; T-ALL, T-cell acute lymphoblastic leukemia.
additional details can be found in Supplementary Table 1.
Including two blastic plasmacytoid dendritic cell neoplasms
one cerebrospinal fluid sample in the validation cohort; two pleural efussion samples in the database cohort.